期刊文献+

端粒酶活性及其结构基因在人脑胶质瘤中的表达 被引量:2

Telomerase activity and expression of subunits in human gliomas
原文传递
导出
摘要 目的 研究分析端粒酶活性及相关结构基因在不同级别脑胶质瘤中的表达 ,探讨端粒酶与脑胶质瘤的相关性及其临床意义。方法 采集 40例脑胶质瘤手术切除标本、4例正常脑组织 ,通过半定量端粒重复序列扩增 (TRAP) 银染方法检测端粒酶活性水平 ;通过半定量逆转录 聚合酶链反应 (RT PCR)检测端粒酶相关结构基因hTR、TP1、hTRT的mRNA表达水平。结果 在40例胶质瘤标本的 3 3例 (82 .5 % )中检测出端粒酶活性 ,而在正常脑组织中无端粒酶活性的表达 ,不同级别脑胶质瘤之间端粒酶活性水平差异有显著性 ,脑胶质瘤端粒酶活性水平与hTRT基因的表达呈显著正相关 ,而与TP1、hTR的表达无显著相关。结论 端粒酶活性可以作为脑胶质瘤的恶性标记之一 ,hTRT基因是一个端粒酶的正调控结构基因 ,hTRT的表达与细胞永生化和恶性肿瘤形成过程中的端粒酶的激活机制有关 ,hTR基因是端粒酶活性必须的组分 。 Objective To study the correlation between telomerase and glioma with detecting the telomerase activity and the expression of telomerase subunits in different grades of glioma. Methods Forty rapidly surgically resected glioma specimens and 4 normal brain tissue were studied. Telomerase activity was detected by semi quantitative telomeric repeat amplification protocol (TRAP) silver staining. The expression of telomerase related major subunitshTR, TP1, hTRTmRNA was detected by using semi quantitative RT PCR. Results Telomerase activity was detectable in 33 of 40 (82.5%) gliomas specimens and not detectable in normal brain tissue. The levels of telomerase expression were associated with the grade of tumor. There was a significant correlation of telomerase activity with hTRT mRNA expression but not with TP1 and hTR expression. Conclusion Telomerase activity can be used as a special marker of gliomas and an index of maligant potential. Up regulation of hTRT may play a critically important role in the development of cell immortality and telomerase reactive, while hTR is required for telomerase but not sufficient by itself, and it's expression level is not corrected with telomerase activity.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2001年第2期147-149,共3页 Chinese Journal of Experimental Surgery
关键词 端粒 末端转移酶 神经胶质瘤 脑胶质瘤 基因表达 Telomerase Telomere Glioma
  • 相关文献

参考文献2

二级参考文献2

  • 1Allsopp R C,Exp Cell Res,1995年,220期,194页
  • 2Wang S,Nature Biotechnol,1998年,16期,196页

共引文献8

同被引文献18

  • 1Neidle S, Kelland LR. Telomerase as an anti- cancer target: current status and future prospects[J]. Anticancer Drug Des, 1999,14(4): 341- 347.
  • 2Komata T, Kanzawa T, Kondo Y, et al. Telomerase as a therapeutic target for malignant gliomas[J]. Oncogene,2002,21 (4) :656 - 663.
  • 3Newbold RF. The significance of telomerase activation and cellular immortalization in human cancer[ J ]. Mutagenesis, 2002, 17 (6): 539 -550.
  • 4Narishetty ST, Panchagnula R. Transdermal delivery system for zidovudine:in vitro,ex vivo and in vivo evaluation[J]. Biopharm Drug Dispos,2004,25(1) :9 - 20.
  • 5Yamaguchi F,Morrison RS,Takahashi H,et al. Anti- telomerase therapy suppressed glioma proliferation[ J ]. Oncol Rep, 1999,6 ( 4 ): 773 -776.
  • 6Neidle S, Parkinson G. Telomere maintenance as a target for anticancer drug discovery[ J]. Nat Rev Drug Discov, 2002,1 (5) :383 - 393.
  • 7Komata T,Kanzawa T,Kondo Y,et al.Telomerase as a therapeutic target for malignant gliomas[J].Oncogene,2002,21(4):656-663.
  • 8Neidle S,Kelland LR.Telomerase as an anti-cancer target:current status and future prospects[J].Anticancer Drug Des,1999,14(4):341-347.
  • 9Newbold RF.The significance of telomerase activation and cellular immortalization in human cancer[J].Mutagenesis,2002,17(6):539-550.
  • 10Holt SE,Shay JW.Role of telomerase in cellular proliferation and cancer[J].J Cell Physiol,1999,180(1):10-18.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部